SKF83959 Produces Antidepressant Effects in a Chronic Social Defeat Stress Model of Depression through BDNF-TrkB Pathway

Bo Jiang, PhD; Fang Wang, MD, PhD; Si Yang, MSc; Peng Fang, MSc; Zhi-Fang Deng, PhD; Jun-Li Xiao, MSc; Zhuang-Li Hu, MD, PhD; Jian-Guo Chen, MD, PhD

Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, Yang, Fang, Deng, Xiao, and Chen); Key Laboratory of Neurological Diseases (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and Chen); The Key Laboratory for Drug Target Researches and Pharmacodynamic Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen); The Institute of Brain Research, Huazhong University of Science and Technology, Wuhan, China (Drs Wang and Chen).

B.J. and F.W. contributed equally to this paper.

Correspondence: Jian-Guo Chen, PhD, Department of Pharmacology, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan, Hubei, China 430030 (chenj@mails.tjmu.edu.cn).

Abstract

**Background:** SKF83959 stimulates the phospholipase Cβ/inositol phosphate 3 pathway, resulting in the activation of Ca\(^{2+}\)/calmodulin-dependent kinase II\(_0\), which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II\(_0\)/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects.

**Methods:** In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/shRNA methods were further used to explore the antidepressive mechanisms of SKF83959.

**Results:** We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D\(_5\) receptor, phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II\(_0\) pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects.

**Conclusion:** These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D\(_5\)/phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II\(_0\)/brain-derived neurotrophic factor pathway.
Keywords: depression; SKF83959; brain-derived neurotrophic factor; chronic social defeat stress

Abbreviations:

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKT</td>
<td>Protein Kinase B</td>
</tr>
<tr>
<td>ANOVA</td>
<td>analysis of variance</td>
</tr>
<tr>
<td>BDNF</td>
<td>brain-derived neurotrophic factor</td>
</tr>
<tr>
<td>CaMKIIα</td>
<td>calcium/calmodulin-dependent kinase IIα</td>
</tr>
<tr>
<td>CMS</td>
<td>chronic mild stress</td>
</tr>
<tr>
<td>CREB</td>
<td>cAMP response element-binding protein</td>
</tr>
<tr>
<td>CSDS</td>
<td>chronic social defeat stress</td>
</tr>
<tr>
<td>DCX</td>
<td>doublecortin</td>
</tr>
<tr>
<td>DG</td>
<td>dentate gyrus</td>
</tr>
<tr>
<td>ERK</td>
<td>extracellular signal-regulated kinase</td>
</tr>
<tr>
<td>FST</td>
<td>forced swim test</td>
</tr>
<tr>
<td>HPA</td>
<td>hypothalamic-pituitary-adrenocortical</td>
</tr>
<tr>
<td>IP3</td>
<td>inositol phosphate 3</td>
</tr>
<tr>
<td>PCPA</td>
<td>P-chlorophenylalanine methyl ester</td>
</tr>
<tr>
<td>PI</td>
<td>phosphatidylinositol</td>
</tr>
<tr>
<td>PLC</td>
<td>phospholipase C</td>
</tr>
<tr>
<td>TrkB</td>
<td>tyrosine kinase B</td>
</tr>
<tr>
<td>TST</td>
<td>tail suspension test</td>
</tr>
</tbody>
</table>

Introduction

Depression is a serious mood disorder that affects 17 to 20% of the population of the world and may result in major social and economic consequences (Blazer et al., 1994). For the pathophysiology of depression, the discovery that chronic antidepressant treatment increases the hippocampal brain-derived neurotrophic factor (BDNF) and phosphorylation of cAMP response element-binding protein (CREB) led to the deduction that a deficiency in neurotrophic factor synthesis and signaling could underlie depression (Nibuya et al., 1995, 1996; Shirayama et al., 2002; Saarelainen et al., 2003). The finding that antidepressants can also increase hippocampal neurogenesis, which is a kind of cellular form of neuroplasticity and necessary for the behavioral improvement, further supports this hypothesis (Santarelli et al., 2003; Dranovsky and Hen, 2006, Perera et al., 2007).

It has been demonstrated that depressive behavior is associated with the downregulation of the PLC/IP3 pathway (Dwivedi et al., 2005). Previous studies suggest that CaMKIIα is not only involved in the synthesis of BDNF (Chen et al., 2012; Yu et al., 2013) but is also modulated by chronic stress (Suenaga et al., 2006; Barbiero et al., 2007; Han et al., 2009). It has also been demonstrated that SKF83959 promotes both striatal and prefrontal BDNF expression through CaMKIIα activation (Rashid et al., 2007b; Hasbi et al., 2009; Perreault et al., 2013). A more recent study showed that SKF83959 elicited antidepressant activity in the forced swim test (FST) and tail suspension test as a novel triple reuptake inhibitor (Fang et al., 2013). Considering the fact that SKF83959 could activate the PLC/IP3/Ca2+/CaMKIIα pathway, which is linked with BDNF signaling, we thus hypothesized that SKF83959 may produce antidepressant-like effects via a mechanism other than as reuptake inhibitor. To address this issue, we first assessed the effects of SKF83959 in a chronic social defeat stress (CSDS) model of depression and then investigated the related molecular mechanisms.

Materials and methods

Animals

Male C57BL/6j mice (9-11 weeks old) and CD1 retired breeder mice (9-13 months old) were obtained from the Animal Center of Tongji Medical College and maintained under standard conditions with a 12-h-light/–dark cycle and ad libitum access to food and water for 1 week before being used. Behavioral testing was performed from 10:00 AM to 5:00 PM concurrent with stated housing conditions and each experimental group consisted of 20 mice. The experiments were carried out in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals and the European Communities Council Directive of 24 November 1986 (86/609/EEC) and were approved by the Animal Care Committee of the University.

Materials

6-Chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF83959) was kindly provided by the National Institute of Mental Health (NIMH) synthesis program. Fluoxetine, 7-chloro-3-methyl-1-phenyl-2,4,5-tetrahydro-3-benzazepin-8-ol (SCH23390), 6-chloro-2,3-dihydro-5-methyl-N-[6-[2-methyl-3-pyridinyl]oxy]-3-pyridinyl]-1H-indole-1-carboxamide (SB242084), 1-[2-[3,4-dichlorophenyl]ethyl]-4-methylpipеразине (BD1063), 1,2-bis-(2-aminophenoxy)ethane-N,N,N,N-tetraethyletyoacetoxymethylacetoxymethylacetoxymethylacetoxymethyl ester (BAPTA-AM), 1-[6-{[(17β)-3-methoxyestr-1,3,5[10]-trien-17yl] amino}hexyl]-1H-pyrole-2,5-dione (U73122), and 2-aminoethoxy-diphenylborate (2-APB) were purchased from Sigma (St. Louis, MO). N-[4-(4-Methyl-1-piperazinyl)phenyl]-9-acridinamine (JP1302) and 3,5-dichloro-N-[25]-1-ethyl-2-pyridinylidinyl methyl]-2-hydroxy-6-methoxybenzamide (raclopride) were purchased from Tocris Bioscience (Bristol, UK). K252a was obtained from Alomone Laboratories (Jerusalem, Israel). The D2 small C-terminally interfering RNA (siRNA) (catalog no: 4457287) and scrambled siRNA (catalog no: 4457287) were obtained from Ambion (Austin, TX). For SKF83959 and fluoxetine, compounds were administered intraperitoneally in a volume of 10 mL/kg. For SCH23390, raclopride, SB242084, BD1063, JP1302, K252a, U73122, BAPTA-AM, and 2-APB, drugs were dissolved in artificial cerebrospinal fluid and bilaterally injected into the hippocampus of C57BL/6j mice.

The experimental procedures are available online in supplementary information.
Results

SKF83959 Produces Antidepressant-Like Effects in Mice

To characterize the antidepressant effects of SKF83959, we utilized the CSDS model, as we previously used (Jiang et al., 2012). As shown in Figure 1A, in the absence of an aggressor, all mice spent similar amounts of time in the interaction zone. Compared to control mice, defeated mice spent about 70±11% less time in the interaction zone when an aggressor was introduced into the cage (n = 10, P < .01 vs control) (Figure 1A). Interestingly, the 14-day treatment of SKF83959 significantly increased the interaction time of defeated mice, similar to fluoxetine (n = 10, P < .01 vs defeated) (Figure 1A).

Over the next 4 days, mice were examined for sucrose preference. Figure 1B showed that the defeated mice displayed a significantly reduced preference for sucrose solution (P < .01 vs control), and this effect was reversed by SKF83959 treatment (n = 10, P < .01 vs defeated). Together, these results suggest that SKF83959 could produce antidepressant effects in the CSDS model of depression.

SKF83959 Counteracts the CSDS-Induced Deficits in Hippocampal Neurogenesis and Dendrite Spine Density

Since adult hippocampal neurogenesis can be upregulated by chronic antidepressant treatment (Malberg et al., 2000), we thus investigated the possible effects of SKF83959 on hippocampal neurogenesis. Neurogenesis was studied by doublecortin immunohistochemistry in the dentate gyrus region, since DCX is a microtubule-associated protein that serves as a marker of neurogenesis by virtue of transient expression in newly formed neurons between the timing of their birth and final maturation (Brown et al., 2003). Figure 2A shows that chronic stress resulted in a 67±3% reduction in the number of DCX+ cells when compared to that in control mice (n = 5, P < .01 vs control). The decreased number of DCX+ cells in the stressed group was reversed by chronic SKF83959 treatment, especially at the dose of 1 mg/kg (n = 5, P < .01 vs defeated) (Figure 2B). Correspondingly, the Western blotting results showed a significant decrease in the hippocampal DCX protein level of stressed mice (n = 5, P < .05 vs control; Figure 2C), which was counteracted by SKF83959 treatment (n = 5, P < .01 vs defeated; Figure 2C).

Previous studies reported that chronic stress induced neuronal atrophy and dendritic arborization of CA3 pyramidal neurons (Magarinos et al., 2011). We thus performed Golgi-Cox staining. As shown in Figure 2D, repeated stress induced a severe decrease in the dendritic spine density of CA3 pyramidal neurons (n = 6, P < .01 vs control), and SKF83959 treatment reversed the reduction of spine density (n = 6, P < .01 vs defeated). These results indicate that the stress-induced decrease in hippocampal neurogenesis and dendritic spine density are also rescued by SKF83959 treatment.

Statistical Analysis

All analyses were performed using SPSS 13.0 software (SPSS Inc) and data are presented as mean ± SEM. Differences between mean values were evaluated using 1-way or 2-way analysis of variance (ANOVA), as appropriate. For all 1-way ANOVAs, posthoc tests were performed using Least Significant Difference test. For all 2-way ANOVAs, Bonferroni posthoc tests were used to assess isolated comparisons. P < .05 was considered statistically significant.

Administration of SKF83959 Enhances BDNF Signaling Pathway and Neurogenesis in the Hippocampus of Adult Normal Mice

Since SKF83959 has been demonstrated to promote BDNF production in striatum and cortex (Hasbi et al., 2009; Perreault et al., 2013), we thus hypothesized that SKF83959 may also enhance hippocampal BDNF expression. As shown in supplementary Figure S1A-B, both the hippocampal BDNF mRNA and protein levels were significantly elevated by SKF83959 administration, especially at the dose of 1 mg/kg (n = 5, P < .01 vs control). The Western blotting results showed that SKF83959 produced a similar increase in the phosphorylated and activated forms of ERK1/2 (pERK1/2), AKT (pAKT), and CREB (pCREB), which are linked to BDNF signaling activation (n = 5, P < .01 vs control) (supplementary Figure S1C) (Shaywitz and Greenberg, 1999). We also detected a significant increase in

Figure 1. 6-Chloro-7, 8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF83959) produces robust antidepressant effects in rodent models of depression. (A) The antidepressant effects of SKF83959 in the social interaction test. Mice were exposed to defeat stress for 10 days and received a daily injection of SKF83959 (0.5, 1 mg/kg, i.p.) for another 14 days; behavioral tests were then conducted. SKF83959-treated mice spent significantly more time engaged in social interaction than vehicle-treated mice. (B) SKF83959 treatment reversed the decrease in sucrose consumption induced by chronic social defeat stress (CSDS). SKF83959-treated mice displayed higher sucrose preference than vehicle-treated mice. Data are expressed as means ± SEM (n = 10); * P < .05, ** P < .01 vs control; # P < .05, ## P < .01 vs defeated + vehicle group. Comparison was made by 2-way analysis of variance (ANOVA) followed by posthoc Bonferroni’s test.
the phosphorylation of hippocampal CaMKIIα (pCaMKIIα) after SKF83959 exposure (n = 5, \( P < .01 \) vs control) (supplementary Figure S1C). Correspondingly, the level of hippocampal DCX protein was increased in SKF83959-treated mice (n = 5, \( P < .01 \) vs control) (supplementary Figure S1C), suggesting that SKF83959 also promotes hippocampal neurogenesis in normal mice.

**SKF83959 Treatment Restores the Stress-Induced Decrease in Hippocampal BDNF Signaling Pathway**

Since the hippocampal BDNF system is involved in the pathophysiology of depression, we measured BDNF mRNA and protein levels in the hippocampus following CSDS. As shown in Figure 3A-B, the average BDNF mRNA and protein levels were decreased in the hippocampus of mice exposed to CSDS compared with control mice (n = 5, \( P < .01 \) vs control), and this was completely reversed by 1 mg/kg SKF83959 (n = 5, \( P < .01 \) vs defeated).

Four members of the neurotrophic factors family have been identified: nerve growth factor (NGF), BDNF, neurotrophins-3 (NT3), and neurotrophins-4 (NT4) (Quartu et al., 2003). These proteins have similar physical characteristics and biological activities. However, we found that although CSDS indeed decreased the levels of NGF, NT3, and NT4 (n = 5, \( P < .01 \) vs control)
Jiang et al. | 5

Copyedited by: OUP

**Figure 3.** 6-Chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF83959) treatment increases the hippocampal brain-derived neurotrophic factor (BDNF) signaling cascade of chronic social defeat stress (CSDS)-treated mice. (A) Chronic SKF83959 administration reversed the decrease in hippocampal BDNF mRNA level induced by CSDS. (B) SKF83959 treatment reversed the CSDS-induced reduction of hippocampal BDNF protein. (C) SKF83959 also restored the CSDS-induced inhibition of hippocampal phosphorylated extracellular signal-regulated kinase (pERK), Protein Kinase B (pAKT), cAMP response element-binding protein (pCREB), and calcium/calmodulin-dependent kinase IIα (pCaMKIIα). Data are expressed as means ± SEM (n = 5); **P< .01 vs control; *P< .05, **P< .01 vs defeated + vehicle group. Comparison was made by 2-way analysis of variance (ANOVA) followed by posthoc Bonferroni's test.

**SKF83959 Produces Antidepressant-Like Effects through Activation of D₅ Receptor in Hippocampus of Mice**

It has been demonstrated that SKF83959 has a high affinity for various receptors in the brain, including the D₁-D₅ heteromer, 5-HT₂C, and α₂C receptors (Hasbi et al., 2009; Chun et al., 2013; Guo et al., 2013). To explore which receptor mediates the antidepressant effects of SKF83959, we firstly used the selective D₁-like (D₁, D₅) receptor antagonist SCH23390 and 5-HT₂C receptor (H3809). However, SKF83959 treatment did not restore the stress-induced changes of BDNF and pCREB in the 2 regions (n = 5) (supplementary Figure S2B-C), suggesting that it is the hippocampus, not mPFC or NAc, that is important for the SKF83959-mediated antidepressant effects.

Other brain regions, like the medial prefrontal cortex (mPFC) and nucleus accumbens (NAc), are also implicated in depression (Di Chiara et al., 1999; Krishnan et al., 2007; Li et al., 2010). As previously reported, chronic stress reduced the expression of BDNF and pCREB in the mPFC (Gourley et al., 2008; Castren and Rantamaki, 2010), while increased BDNF and pCREB levels were detected in the NAc (Newton et al., 2002; Eisch et al., 2003; Krishnan et al., 2007). However, SKF83959 treatment did not restore the stress-induced changes of BDNF and pCREB in the 2 regions (n = 5) (supplementary Figure S2B-C), suggesting that it is the hippocampus, not mPFC or NAc, that is important for the SKF83959-mediated antidepressant effects.
the SKF83959-induced effects in the FST (n = 10, $P < .01$ vs control) (Figure 4A). The SKF83959-induced increase in sucrose preference (Figure 4B) and social interaction (Figure 4C) were also prevented by SCH23390, not raclopride (n = 10). The SCH23390-induced effects indicate that the antidepressant effects of SKF83959 are mediated through the D$_1$-D$_2$ heteromer or D$_5$ receptor or both. The raclopride-induced effects further indicate that the D$_1$-D$_2$ heteromer is not necessary for the SKF83959-mediated effects. Similarly, pretreatment with SCH23390, not raclopride, abolished the SKF83959 effects on hippocampal BDNF expression of normal mice (n = 5; supplementary Figure S1D), hippocampal BDNF expression (n = 5; Figure 4D), and CREB phosphorylation (n = 5; Figure 4E) of CSDS-defeated mice.

Figure 4. Blockade of hippocampal D$_1$-like receptor, not D$_2$-like receptor, prevents the antidepressant effects of 6-Chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF83959). (A) Mice were daily pretreated with the antagonist of D$_1$-like receptor (7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol [SCH23390]) or D$_2$-like receptor (raclopride) for 3 days before SKF83959 (1 mg/kg, i.p.) administration, respectively. Pretreatment with SCH23390, not raclopride, prevented the SKF83959-induced decrease in immobility duration in the forced swim test (FST) test (n = 10). (B) CSDS-treated mice were co-injected with SKF83959 and SCH23390/raclopride for 14 days. Administration of SCH23390, not raclopride, blocked the behavioral effects of SKF83959 in the sucrose preference test (n = 10). (C) Administration of SCH23390, not raclopride, blocked the behavioral effects of SKF83959 in the social interaction test (n = 10). (D) The effects of SKF83959 on hippocampal brain-derived neurotrophic factor (BDNF) expression were blocked by SCH23390, not raclopride (n = 5). (E) The effects of SKF83959 on hippocampal pCREB level were also abolished by SCH23390, not raclopride (n = 5). Data are expressed as means ± SEM; **$P < .01$ vs control; ***$P < .01$ vs defeated + vehicle group. Comparison was made by 2-way analysis of variance (ANOVA) followed by posthoc Bonferroni’s test.
To further determine whether SKF83959 produces effects through the D₅ receptor, D₅ siRNA was injected into the hippocampus to interrupt the D₅ receptor. Figure 5A showed the effectiveness of D₅ siRNA (n=5, P<0.01 vs control). As shown in Figure 5B, while D₅ or scrambled siRNA (2 nmol/mouse) alone produced no effects on the immobility, D₅ siRNA pretreatment prevented the antidepressant effects of SKF83959 in the FST (n=8, P<0.01 vs control). Moreover, D₅ siRNA also abolished the SKF83959 effects in the sucrose preference test (n=8, Figure 5C) and social interaction test (n=8, Figure 5D).

Next, the 5-HT₂C receptor antagonist SB242084 (5 nmol/mouse), α₁C receptor antagonist JP1302 (5 nmol/mouse), and sigma-1 receptor antagonist BD1063 (5 nmol/mouse) were used. It was found that neither of these antagonists produced influence on the SKF83959-induced shortening of immobility in the FST (n=10) (supplementary Figure S3A). Similarly, these antagonists could not block the antidepressant effects of SKF83959 in the sucrose preference test (n=10; supplementary Figure S3B) and social interaction test (n=10; supplementary Figure S3C). Together, these results indicate that SKF83959 produces antidepressant effects through D₅ receptor.
The SKF83959-Mediated Antidepressant-Like Effects Require Activation of the PLC Signaling Pathway

SKF83959 is known to stimulate PI-hydrolysis via phospholipase Cβ and results in the production of IP₃, which subsequently induces intracellular calcium release (Jin et al., 2003; Zhen et al., 2004). Then, we employed the inhibitors of the PLC signaling pathway to assess the role of the PLC/IP3 pathway in SKF83959-mediated behavioral effects. As shown in Figure 6A, while PLC inhibitor U73122 (5 nmol/mouse) infusion alone had no detectable effects on immobility in the FST, it dramatically prevented the SKF83959-induced shortening of immobility time.

Figure 6. The 6-Chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF83959)-induced antidepressant effects require the phospholipase C (PLC) signaling. (A) Mice were daily pretreated with the inhibitors of PLC (U73122), IP₃ (2-APB), or the intracellular Ca²⁺ chelator (BAPTA-AM) for 3 days before SKF83959 (1 mg/kg, i.p.) administration, respectively. Pretreatment with these inhibitors prevented the SKF83959-induced decrease of immobility duration in the FST test (n = 10). (B) CSDS-treated mice were co-injected with SKF83959 and PLC signaling inhibitors for 14 days. Administration of U73122, 2-APB, or BAPTA-AM blocked the behavioral effects of SKF83959 in the sucrose preference test (n = 10). (C) Administration of PLC signaling inhibitors also blocked the antidepressant-like effects of SKF83959 in the social interaction test (n = 10). (D) The effects of SKF83959 on hippocampal brain-derived neurotrophic factor (BDNF) expression were blocked by U73122, 2-APB, or BAPTA-AM, respectively (n = 5). (E) The effects of SKF83959 on hippocampal phosphorylated cAMP response element-binding protein (pCREB) level were also abolished by PLC signaling inhibitors (n = 5). Data are expressed as means ± SEM; ** P < .01 vs control; * P < .05, ** P < .01 vs defeated + vehicle group. Comparison was made by 2-way analysis of variance (ANOVA) followed by posthoc Bonferroni’s test.
As shown in Figure 8C, while TrkB shRNA or control expression was further confirmed (n = 5, P < 0.01 vs control), suggesting that the SKF83959-stimulated BDNF upregulation involves the activation of the PLC/IP3/Ca2+ pathway. Figure 6D shows that pretreatment with 2-APB, BAPTA-AM, or U73122 prevented the SKF83959-induced effects on hippocampal BDNF expression of stressed mice. Parallel to BDNF, infusion of U73122, 2-APB, and BAPTA-AM also blocked the SKF83959 effects on hippocampal CREB phosphorylation (n = 5) (Figure 6E). Together, these results demonstrate that the PLC/IP3 pathway is necessary for the SKF83959-mediated antidepressant effects.

**BDNF-TrkB System Is Necessary for the SKF83959-Mediated Antidepressant-Like Effects**

To determine whether the BDNF-TrkB system is necessary for the antidepressant-like effects of SKF83959, K252a, a potent pharmacological inhibitor of the BDNF receptor TrkB (Tapley et al., 1992), was used. As shown in Figure 7A, while K252a (5 nmol/mouse) alone had no effects on the immobility, it prevented the antidepressant effects of SKF83959 in the FST (n = 10, P < 0.01 vs control), sucrose preference test (n = 10; Figure 7B), and social interaction test (n = 10; Figure 7C). Moreover, the SKF83959-induced increase in hippocampal BDNF expression of defeated mice was also blocked by K252a treatment (n = 5; Figure 7D). In line with this, K252a also abolished the effects of SKF83959 on the expression of hippocampal pERK1/2, pAKT, and pCREB (n = 5; Figure 7D).

In a parallel experiment, the effects of K252a on the SKF83959-induced increase in neurogenesis were investigated. As shown in supplementary Figure S4A-C, the SKF93959-induced increase in the Dcx+ cell number (n = 5) and Dcx protein level (n = 5) in the DG of defeated mice were blocked by chronic K252a injections. Next, the Golgi-Coxl staining showed that K252a treatment also prevented the SKF93959-induced increase in hippocampal dendritic spine density (n = 6; supplementary Figure S4D-E) of defeated mice.

Furthermore, we used the lentiviral expression of specific short hairpin RNAs (shRNAs) against TrkB to downregulate the hippocampal BDNF-TrkB system. The expression of lentivirus-delivered shRNAs was stable at day 14 after the injection (Figure 8A), and their efficacy in downregulating the TrkB expression was further confirmed (n = 5, P < 0.01 vs control) (Figure 8B). As shown in Figure 8C, while TrkB shRNA or control shRNA (3 x 10^5 TU/mouse) alone had no effects on the immobility duration, pretreatment of TrkB shRNA fully abolished the antidepressant effects of SKF83959 in the FST (n = 9, P < 0.01 vs control). Also, TrkB shRNA abolished the effects of SKF83959 in the sucrose preference test (n = 9; Figure 8D) and social interaction test (n = 9; Figure 8E). Collectively, these results indicate that the BDNF-TrkB pathway is necessary for the SKF83959-mediated neurogenic and antidepressant effects.

**Discussion**

In the present study, we demonstrated that SKF83959 produced robust antidepressant effects in the CSDS model of depression. It was found that chronic treatment of SKF83959 could reverse the CSDS-induced decrease of hippocampal neurogenesis and dendritic spine density and also restored the stress-induced decrease in hippocampal BDNF signaling cascade. By using various inhibitors and siRNA/shRNA methods, we further confirmed that these effects were mediated by activating the D1 receptor, PLC/IP3/CaMKIIα pathway, and BDNF-TrkB system. We also found that the hippocampus was important for the SKF83959-mediated effects.

The conclusion that SKF83959 has antidepressant effects in the CSDS model of depression should be reliable and believable, since Fang et al. (2013) reported that SKF83959 could reduce the immobility of mice in the FST and tail suspension test, two widely used behavioral assays for detecting potential antidepressant-like activity, and have high predictive validity for antidepressant activity. Pharmacological and biological blockade of hippocampal D1 receptor abolished the antidepressant effects of SKF83959. This is very interesting and may suggest that the hippocampal D1 receptor can be a target for antidepressants. SKF83959 also activates the D1-D2 heteromer, and one recent paper demonstrated that uncoupling the D1-D2 heteromer complex in the PFC exerted antidepressant effects (Pei et al., 2010), which is in contrast to our study. One explanation for this discrepancy may be that the hippocampal SKF83959-D1 receptor activation-induced effects exceed the prefrontal SKF83959-D1 heteromer activation-induced effects. The behavioral data of Figure 4 may support this explanation, since the immobility time of SKF83959 + raclopride co-treated group was even less than the SKF83959-treated group in the FST (SKF83959, 49.1 ± 9.8 seconds; SKF83959 + raclopride, 32.1 ± 7.3 seconds; Figure 4A), and the sucrose consumption and social interaction of SKF83959 + raclopride + CSDS group were even higher than the SKF83959 + CSDS group (Figure 4B-C), indicating that blockade of the D1-D2 heteromer antagonized the SKF83959-D1 heteromer activation-induced prodepressive effects.

Using the PLC/IP3 pathway inhibitors, we found that SKF83959 produced antidepressant effects through this signaling pathway. This is consistent with previous reports showing that repeated stress reduced both the activity and expression of PLC in the frontal cortex and hippocampus of animals, and elevation of IP3 by administrating inositol reduced depressive-like behaviors in animal models of depression (Landwich et al., 2005). For the downstream pharmacological target of SKF83959, we selected BDNF in our study, as (1) SKF83959 induces the activation of CaMKIIα, which could affect the expression of BDNF (Chen et al., 2012; Yu et al., 2013), and (2) SKF83959 promotes the striatal BDNF expression of normal mice through D1-D2 heteromer (Hasbi et al., 2009) and also promotes the prefrontal BDNF expression of normal mice through D1 receptor (Perreault et al., 2013). Our Western blotting data revealed that SKF83959 affected the BDNF system in the hippocampus, not PFC or NAc, of depressed mice. The nonsensitization of enhanced prefrontal and striatal BDNF expression of defeated mice after SKF83959 treatment is interesting. The explanation may be that chronic stress led to decreased D1-like dopaminergic function in the PFC and also decreased D1 receptor expression in the NAc (Papp et al., 1994; Mizoguchi et al., 2002), suggesting the downregulated function and response to SKF83959 of prefrontal D1 receptor/striatal D1-D2 heteromer under depressive conditions compared to normal conditions. Besides, it was found that SKF83959 had no influence on the NGE, NT3, and NT4, 3 other neurotrophic factors, indicating that the antidepressant role of SKF83959 is not only regionally selective but also biologically selective.

Chronic stress affects the neurogenic and neurotrophic pathways that maintain ionic homeostasis (Duman and Monteggia,
The immunohistochemical data revealed that SKF83959 promoted the hippocampal neurogenesis of both the depressed mice and normal mice, suggesting that SKF83959 may also be developed as a proneurogenic compound. Depression is also accompanied with hippocampal neuronal atrophy and dendritic arborization (Magarinos et al., 2011). Our results showed a significant antidepressant effect of SKF83959 by increasing the spine density of CA3 pyramidal neurons. This observation is consistent with previous studies showing that activation of dopamine signaling and CaMKIIα in the neurons of NAc leads to enhanced neuronal differentiation and spine density (Schmidt et al., 1996; Ciani et al., 2011). Moreover, the usage of K252a found that these SKF83959-induced neurogenic and neurotrophic effects were all mediated through the BDNF system. In addition, repeated administration of SKF83959 has been shown to result in desensitization of the behavioral and...
molecular effects of the drug, but this is not likely involved in the effect of SKF83959 in the present study, because our experiments demonstrated that the antidepressant effects of SKF83959 are mediated through activating the D5 receptor. In summary, our study reveals a new action of SKF83959 on central nervous system, which may lead to the development of new treatments for depression and other psychiatric disorders. Moreover, in addition to depression, the BDNF and dopaminergic systems are...
implicated in some other neurodegenerative dysfunctions, like Alzheimer’s disease (Voiyeskos et al., 2011), so it is possible that SKF83959 may also produce effects in these disorders.

**Supplementary Material**

For supplementary material accompanying this paper, visit http://www.ijnp.oxfordjournals.org/

**Acknowledgments**

This work was supported by grants from the National Basic Research Program of China (973 Program, No. 2013CB531303 to J.G.C., No. 2014CB744601 to F.W.) and the International Science and Technology Cooperation Program of China (No. 2011DFA32670) and the Program for Changjiang Scholars and Innovative Research Team in University (IRT13016) to Dr. J.G.C. It was also supported by an NSFC grant to Dr. F.W. (No. 81222048).

**Statement Interest**

None.

**References**


